{"id":"clocapramine","rwe":[{"pmid":"38373093","year":"2025","title":"Unlocking therapeutic potential: computational insights into TREM2 protein targeting with FDA-approved drugs for neurodegeneration.","finding":"","journal":"Journal of biomolecular structure & dynamics","studyType":"Clinical Study"},{"pmid":"33964682","year":"2021","title":"Efficacy and safety of antipsychotic treatments for schizophrenia: A systematic review and network meta-analysis of randomized trials in Japan.","finding":"","journal":"Journal of psychiatric research","studyType":"Clinical Study"},{"pmid":"28553116","year":"2017","title":"Comparative efficacy and safety of antipsychotics in the treatment of schizophrenia: a network meta-analysis in a Japanese population.","finding":"","journal":"Neuropsychiatric disease and treatment","studyType":"Clinical Study"},{"pmid":"25525363","year":"2014","title":"Iminodibenzyl class antipsychotics for schizophrenia: a systematic review and meta-analysis of carpipramine, clocapramine, and mosapramine.","finding":"","journal":"Neuropsychiatric disease and treatment","studyType":"Clinical Study"},{"pmid":"17610675","year":"2007","title":"Augmentation of paroxetine with clocapramine in panic disorder.","finding":"","journal":"Psychiatry and clinical neurosciences","studyType":"Clinical Study"}],"tags":[{"label":"clocapramine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"clocarpramine","offLabel":[],"synonyms":["clocapramine hydrochloride","clocapramine HCl","clocapramine","clocarpramine"],"timeline":[],"approvals":[],"brandName":"Clocarpramine","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"clocapramine","explanation":"Imagine your brain is a busy city with many different streets and intersections. Neurotransmitters are like the traffic signals that help different parts of the brain communicate with each other. Clocapramine may help regulate the flow of traffic by adjusting the signals that control the movement of neurotransmitters.","oneSentence":"Clocapramine is thought to work by modulating the activity of certain neurotransmitters in the brain.","technicalDetail":"Clocapramine is a serotonin receptor modulator, but the specific receptor subtypes and mechanisms involved are not well understood."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/687","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CLOCAPRAMINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T10:09:27.980109","biosimilars":[],"competitors":[],"genericName":"clocapramine","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"6EEL1GB72K","CHEBI":"CHEBI:135778","INN_ID":"3272","UMLSCUI":"C0047305","ChEMBL_ID":"CHEMBL2104103","KEGG_DRUG":"D07718","DRUGBANK_ID":"DB09003","PUBCHEM_CID":"2793"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":25,"therapeuticAreas":["Neuroscience"],"biosimilarFilings":[],"recentPublications":[{"date":"2025 Aug","pmid":"38373093","title":"Unlocking therapeutic potential: computational insights into TREM2 protein targeting with FDA-approved drugs for neurodegeneration.","journal":"Journal of biomolecular structure & dynamics"},{"date":"2021 Jun","pmid":"33964682","title":"Efficacy and safety of antipsychotic treatments for schizophrenia: A systematic review and network meta-analysis of randomized trials in Japan.","journal":"Journal of psychiatric research"},{"date":"2017","pmid":"28553116","title":"Comparative efficacy and safety of antipsychotics in the treatment of schizophrenia: a network meta-analysis in a Japanese population.","journal":"Neuropsychiatric disease and treatment"},{"date":"2014","pmid":"25525363","title":"Iminodibenzyl class antipsychotics for schizophrenia: a systematic review and meta-analysis of carpipramine, clocapramine, and mosapramine.","journal":"Neuropsychiatric disease and treatment"},{"date":"2007 Aug","pmid":"17610675","title":"Augmentation of paroxetine with clocapramine in panic disorder.","journal":"Psychiatry and clinical neurosciences"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Clocapramine is a small molecule drug in the clocapramine class, but its target and exact mechanism of action are unknown. It is not FDA-approved for any indications. The commercial status of clocapramine is unclear, and it may be patented or off-patent. As a result, there is limited information available on its safety profile and pharmacokinetic properties. Further research is needed to fully understand the potential benefits and risks of clocapramine.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}